Iovance Announces Data Showing Durable Responses with Lifileucel TIL Cell Therapy in Advanced Soft Tissue Sarcomas at ESMO 2026
Iovance reported pilot data at ESMO 2026 showing one-time lifileucel monotherapy achieved a 50% confirmed ORR across the first eight evaluable patients with refractory metastatic UPS and DDLPS. All four partial responses remained ongoing at 6+ to 46+ weeks as of the September 9, 2026 data cut-off, and the safety profile was consistent with lifileucel in other indications.
Key figures
- Drug Name
- lifileucel
- Phase Of Trial
- pilot trial; registrational Phase 2 (SARATOGA, NCT07741877)
- Orr
- 50%
- Evaluable patients
- 8
- Ongoing response durations weeks
- [6,26,40,46]
AI analysis
Red flags1 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.